Search - tctmd.com

Displaying 301 - 320 of 363

Sort: Relevancy | Date

News Daily News

Thin-Cap Fibroatheromas May Help Explain Poor PCI Outcomes in Diabetic Patients

Todd Neale

July 06, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Guidelines Notwithstanding, More Diabetics with Multivessel CAD Receive PCI Than CABG

Yael L. Maxwell

May 13, 2016

News Industry News

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

May 06, 2016

News Daily News

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Michael O'Riordan

March 25, 2016

News Industry News

Victoza® Significantly Reduced the Risk of Major Adverse Cardiovascular Events in the LEADER Trial

March 06, 2016

News Daily News

Diabetes More Influential Than CAD Complexity in DES-Treated Patients

L.A. McKeown

February 03, 2016

News Industry News

U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)

January 24, 2016

News Industry News

Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

September 29, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Conference News ESC 2015

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

Yael L. Maxwell

September 01, 2015

News Conference News ESC 2015

TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics

Yael L. Maxwell

August 31, 2015

News Daily News

Registry Study Suggests Absorb BVS Matches DES in Diabetic All-Comers

August 27, 2015

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

News Industry News

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

August 20, 2015

News Daily News

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

Todd Neale

August 17, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

Advertisement

Thin-Cap Fibroatheromas May Help Explain Poor PCI Outcomes in Diabetic Patients

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Guidelines Notwithstanding, More Diabetics with Multivessel CAD Receive PCI Than CABG

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Victoza® Significantly Reduced the Risk of Major Adverse Cardiovascular Events in the LEADER Trial

Diabetes More Influential Than CAD Complexity in DES-Treated Patients

U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)

Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes

TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics

Registry Study Suggests Absorb BVS Matches DES in Diabetic All-Comers

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

High Troponin T Foretells Poor Outcomes in Patients With Type 2 Diabetes, Stable Heart Disease

Novel Antisense Inhibitor Cuts High Triglyceride Levels

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content